ADAMTS9
protein-codingADAM metallopeptidase with thrombospondin type 1 motif 9, the group of ADAM metallopeptidases with thrombospondin type 1 motif
Gene summary
This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. Members of the ADAMTS family have been implicated in the cleavage of proteoglycans, the control of organ shape during development, and the inhibition of angiogenesis. This gene is localized to chromosome 3p14.3-p14.2, an area known to be lost in hereditary renal tumors. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Jan 2016]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~172.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0005308
Submitter: ClinGen
*ADAMTS9* gene is located on chromosome 3 at 3p14.1 and encodes ADAMTS family the DAM Metallopeptidase With Thrombospondin Type 1 Motif 9, an enzyme belonging to the ADAMTS family. The secreted metalloprotease that plays a role in ciliogenesis by localizing to the base of the cilium. Bi-allelic variants in *ADAMTS9* are associated with a nephronophthisis-related ciliopathy disease in humans. This gene-disease pair was first proposed in 2019 (Choi et al., 2019; PMID: 30609407). Patients in this study shared common phenotypes including proteinuria, end stage renal disease, gross morphological defects in the kidneys and extra-renal features including deafness, and short stature. In contrast, another study (PMID: 34750010) describes bi-allelic variants in *ADAMTS9* being associated with Joubert syndrome-like presentation (complete with the neurological and ocular features) without the renal manifestations. In total, five unrelated individuals harboring bi-allelic variants in *ADAMTS9* have been reported in the literature presenting with renal and/or extra-renal symptoms (PMID: 30609407, 37035301,37230223, 34750010). To date, eight unique variants have been described associated with disease and were scored in the curation (six missense, one nonsense, one frameshift). This gene-disease relationship is also supported by experimental data. ADAMTS9 knockout kidney organoids demonstrated abnormal cilia, and ciliogenesis that is not rescued by ADAMTS9 variants (PMID: 37035301). ADAMTS9 is shown to be expressed in podocytes and proximal tubules, influences the Wnt/PCP pathway, regulates the localization of junction proteins (PMID: 37035301). Biochemical assays further demonstrate the ADAMTS9-mediated cleavage that separates TMEM67 into a C-terminal portion for ciliary transition zone assembly and a full-length form for Wnt signaling (PMID: 40436881). A novel mouse model in preprint demonstrates the loss of ADAMTS9 disrupts ciliogenesis and collagen homeostasis resulting in nephronophthisis-like polycystic kidneys (PMID: 41542618). Functional studies performed with transgenic animal models have investigated the role of ADAMTS9 in development, particularly in the context of the cardiac, cartilage, bone development (PMID: 20096780). The first study linking ADAMTS9 to disease (PMID: 30609407) performed functional studies using patient-derived fibroblasts. These studies demonstrated that patient fibroblasts have reduced primary cilia, suggesting a role for ADAMTS9 in cilia formation (PMID: 30609407). A morpholino-mediated knockdown of ADAMTS9 in zebrafish that caused curved body axis, hydrocephalus, and pronephric cysts (PMID: 33290818). In summary, there is definitive evidence supporting the relationship between *ADAMTS9* and autosomal recessive ciliopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. The curation was originally evaluated by the ClinGen Kidney Cystic and Ciliopathy Disorders GCEP on the meeting date 05/11/2022 (SOP Version 8). It was re-evaluated on 04/22/2026 (SOP version 12). As a result, the classification increased from Limited to Definitive with the addition of two case reports (PMIDs: 37230223, 37035301) and several functional studies (PMIDs: 37035301, 40436881, 41542618).
Inheritance Pattern: AR
Disease ID:MONDO:0022409
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0019005
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0009728
Submitter: Orphanet
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ADAMTS9 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_182920.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 67 | 16 | 87 | ||
| missense | 326 | 19 | 11 | 356 | ||
| nonsense | 3 | 3 | ||||
| start loss | 0 | |||||
| frameshift | 1 | 1 | 2 | |||
| splice donor/acceptor (+/-2bp) | 3 | 3 | ||||
| Total | 0 | 1 | 337 | 86 | 27 | 451 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_891550.1 | 39 | MANE Select | |
| Ensembl | ENSP00000418735.1 | 39 | MANE Select | |
| RefSeq | NP_001305710.1 | 38 | Standard | |
| Ensembl | ENSP00000295903.4 | 38 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| adamts9 | Danio rerio | Structure: pancreatic B cell Quality: decreased area abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Post-translational protein modification
- Metabolism of proteins
- Extracellular matrix organization
- Degradation of the extracellular matrix
- O-glycosylation of TSR domain-containing proteins
Biological Process
- heart valve morphogenesis
- ventricular cardiac muscle tissue development
- proteolysis
- glycoprotein catabolic process
- multicellular organism development
Molecular Function
- metalloendopeptidase activity
- metallopeptidase activity
- zinc ion binding
Cellular Component
- extracellular space
- endoplasmic reticulum
- cell surface
- extracellular matrix
- intracellular membrane-bounded organelle
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000498707
- Coding exons
- 39
- Length
- 172344
- Individuals with no LoFs
- 125668
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 80
- Defined
- 125748
- p
- 0.000318
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.955 | 1030 | 1.12e+3 | 0.920 | 0.0000634 | 12696 |
| Missense (PolyPhen) | 240 | 402.7 | 0.59598 | 4536 | ||
| Synonymous | -3.09 | 495 | 415 | 1.19 | 0.0000245 | 3598 |
| Loss of Function | 7.13 | 35 | 119 | 0.294 | 0.00000657 | 1327 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00018 | 0.00018 | rare |
| Latino/Admixed American | 0.00055 | 0.00052 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00033 | 0.00033 | rare |
| Finnish | 0.00018 | 0.00018 | rare |
| European (Non-Finnish) | 0.00030 | 0.00028 | rare |
| South Asian | 0.00051 | 0.00049 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Cleaves the large aggregating proteoglycans, aggrecan (at the '1838-Glu-|-Ala-1839' site) and versican (at the '1428- Glu-|-Ala-1429' site). Has a protease-independent function in promoting the transport from the endoplasmic reticulum to the Golgi apparatus of a variety of secretory cargos. {ECO:0000269|PubMed:12514189, ECO:0000269|PubMed:22419820}.;
Intolerance Scores
- LoFtool
- 0.651
- RVIS EVS
- -2.39
- RVIS percentile EVS
- 1.08
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.352
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |